Ring Carbon Of Each Of The Two Nitrogen Containing Hetero Rings Is Bonded Directly To Chalcogen (e.g., Both Rings May Be Bonded To The Same Oxygen Atom Or To Different Oxygen Atoms, Etc.) Patents (Class 548/519)
-
Patent number: 11548890Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.Type: GrantFiled: July 12, 2021Date of Patent: January 10, 2023Assignee: Nimbus Saturn, Inc.Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
-
Patent number: 11498898Abstract: The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.Type: GrantFiled: September 15, 2020Date of Patent: November 15, 2022Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tomomi Ikemoto, Hideya Mizufune, Toshiaki Nagata, Takeshi Yamasaki
-
Patent number: 10550348Abstract: The present invention relates to a lubricating composition containing (a) an oil of lubricating viscosity; and (b) a compound selected from the group consisting of: (i) an ester-containing heterocycle; (ii) an amide-containing heterocycle; and (iii) a pyrimidine, wherein the ester-containing heterocycle and the amide-containing heterocycle have a hydrocarbyl group containing 6 to 40 carbon atoms. The invention further provides for a method of supplying an internal combustion engine with the lubricating composition.Type: GrantFiled: April 24, 2018Date of Patent: February 4, 2020Assignee: The Lubrizol CorporationInventors: Patrick E. Mosier, Jason R. Brown, Matthew D. Gieselman, Calvin W. Schroeck, Seth L. Crawley, William R. S. Barton, William C. Ward, Jr.
-
Patent number: 9351484Abstract: Described is a class of symmetrical and asymmetrical N-alkyl lactam ethers. One preferred ether is bis-N-ethyl pyrrolidone ether. Preferred compositions and uses of the ethers are in performance chemicals, personal care, and pharmaceutical fields, where they function a variety of roles, including as a solvent, solubilizer, freezing point depressor, diluent, extracting agent, cleaning agent, degreaser, absorbent and/or dispersion agent.Type: GrantFiled: October 18, 2013Date of Patent: May 31, 2016Assignee: ISP INVESTMENTS INC.Inventors: Osama M. Musa, Kolazi S. Narayanan
-
Patent number: 9266831Abstract: The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.Type: GrantFiled: June 12, 2014Date of Patent: February 23, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Tomomi Ikemoto, Toshiaki Nagata, Naohiro Fukuda
-
Patent number: 9260416Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.Type: GrantFiled: May 21, 2012Date of Patent: February 16, 2016Assignee: AMIRA PHARMACEUTICALS, INC.Inventors: Jeffrey Roger Roppe, Timothy Andrew Parr, John Howard Hutchinson
-
Patent number: 9181255Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: GrantFiled: December 17, 2010Date of Patent: November 10, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Zhe Nie, Christopher Smith, Masashi Takahashi, Qing Dong, Victoria Feher
-
Patent number: 9068137Abstract: The invention relates to compositions containing a basic oil or base oil, 10 to 50 percent by weight of ether pyrrolidone carboxylic acids of formula (1) or the salts thereof of formula (1), wherein R1 represents C8-C30-alkyl, C8-C30-alkenyl, C6-C30-alyl, C7-C30-alkylaryl, M represents hydrogen, alkali metal, alkaline earth metal, or ammonium, X represents C2-C6-alkylene, or a poly(oxyalkylene) group of formula (2), wherein I is a number ranging from 1 to 50, m, n are numbers ranging from 0 to 50 independently of l and independently of one another, R2, R3, and R4 independently represent hydrogen, CH3, or CH2CH3, Y represents C2-C6-alkylene, said compositions further containing a specific amount of a pH regulator/neutralizer such that a 5 percent by weight emulsion of the composition in deionized water has a pH ranging from 7 to 11.Type: GrantFiled: May 19, 2010Date of Patent: June 30, 2015Assignee: Clariant Finance (BVI) LimitedInventors: Rainer Kupfer, Carsten Cohrs, Alexander Roesch
-
Patent number: 9012490Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.Type: GrantFiled: March 11, 2013Date of Patent: April 21, 2015Assignee: Howard UniversityInventors: Evaristus A. Nwulia, Amol Kulkarni
-
Patent number: 8946446Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 13, 2012Date of Patent: February 3, 2015Assignee: Phenex Pharmaceuticals AGInventors: Christoph Steeneck, Olaf Kinzel, Christian Gege, Gerald Kleymann, Thomas Hoffmann
-
Patent number: 8758880Abstract: Monomeric or polymeric compounds comprising at least one moiety of the formula (Ia) wherein X is CR, where R is H or a substituent as defined in claim 1, or is another ketopyrrole moiety e.g. of the formula (Ib) or (Ic) with this moiety and all other symbols are as defined in claim 1, show good solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).Type: GrantFiled: October 16, 2008Date of Patent: June 24, 2014Assignee: BASF SEInventors: Jean-Charles Flores, Ulrich Berens, Frank Bienewald, Hans Jürg Kirner, Mathieu G. R. Turbiez
-
Patent number: 8685992Abstract: The present invention refers to compounds derived from trisubstituted 1H-pyrrole rings and aromatic rings, which have the following formula (I): wherein: R1 and R2 represent, independently, an optionally substituted C6-C10 aryl radical or an optionally substituted heteroaryl radical; A and M represent, independently, a methylene group or a single bond, in which case the adjacent aromatic ring would be attached directly to the amide group; the Y?Z group represents together and indistinctly an oxygen atom, a sulfur atom, a cis-vinylidene group, an imino group, or a methine group with a sp2-hybridized carbon atom; X represents indistinctly a methine group, a cis-vinylidene group or a nitrogen atom; and W represents a hydroxyl group, an optionally substituted C1-C6 alkyl group, an optionally substituted heteroaryl group or an optionally substituted C6-C10 aryl group; or a salt, solvate or prodrug thereof, as well as to the process for their preparation and the use thereof for the treatment of cancer.Type: GrantFiled: October 1, 2010Date of Patent: April 1, 2014Assignees: Universidad del País Vasco, Ikerschem, S.L.Inventors: Fernando Pedro Cossío Mora, Aizpea Zubia Olascoaga, Yosu Vara Salazar, Eider Ion San Sebastián Larzabal, Dorleta Otaegui Ansa, María del Carmen Masdeu Margalef, Eneko Aldaba Arévalo
-
Publication number: 20140079723Abstract: Methods and materials for treating various diseases and medical conditions with meso-biliverdin compositions. In addition methods and materials for producing meso-biliverdin are provided where the methods include reacting phycocyanobilin with an amphoteric compound in a solvent to yield meso-biliverdin are provided.Type: ApplicationFiled: September 16, 2013Publication date: March 20, 2014Applicant: UTAH STATE UNIVERSITYInventors: Jon Y. Takemoto, Dong Chen, Cheng-Wei T. Chang, Jonathan Wood
-
Publication number: 20140051742Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.Type: ApplicationFiled: March 11, 2013Publication date: February 20, 2014Inventors: Evaristus A. Nwulia, Amol Kulkarni
-
Publication number: 20140045698Abstract: Described is a class of symmetrical and asymmetrical N-alkyl lactam ethers. One preferred ether is bis-N-ethyl pyrrolidone ether. Preferred compositions and uses of the ethers are in performance chemicals, personal care, and pharmaceutical fields, where they function a variety of roles, including as a solvent, solubilizer, freezing point depressor, diluent, extracting agent, cleaning agent, degreaser, absorbent and/or dispersion agent.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: ISP INVESTMENTS INC.Inventors: Osama M. Musa, Kolazi S. Narayanan
-
Publication number: 20130324687Abstract: The invention provides compounds and monomers having a carbonate linkage. The monomers can be used to form homopolymers or can be coupled with other monomers to provide a wide variety of non-homopolymers. The invention further provides a wide variety of compositions comprising the compounds, monomers, and polymers. In the exemplary structures below, Q, A, R, and n are as described herein.Type: ApplicationFiled: January 17, 2012Publication date: December 5, 2013Applicant: ISP Investments Inc.Inventors: Ezat Khosravi, Osama M. Musa
-
Patent number: 8575349Abstract: The present invention relates to novel derivatives of 1-alkyl-6-oxo-piperidine-3-carboxylic acids and 1-alkyl-5-oxo-pyrrolidine-3-carboxylic acids represented by Formula I: wherein n is an integer of 1 or 2; R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen and methyl; X is selected from the group consisting of oxygen and nitrogen; and R5 is hydrogen or a C1-C7 linear or branched acyclic hydrocarbon group, or R5 together with X form a 3- to 8-membered heterocyclic hydrocarbon group, and their uses as cooling compounds.Type: GrantFiled: November 22, 2010Date of Patent: November 5, 2013Assignee: International Flavors & Fragrances Inc.Inventor: Arkadiusz Kazimierski
-
Publication number: 20130289223Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y-[Yn-LINK B-X]m-LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio-LINK A-Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial activity in vivo.Type: ApplicationFiled: December 17, 2012Publication date: October 31, 2013Inventors: J. Paul SANTERRE, Mei LI
-
Publication number: 20130289284Abstract: Provided are modified natural compounds that are produced, at least in part, from (A) at least one epoxidized and/or maleated natural fatty acid, or epoxidized and/or maleated natural oil, and (B) at least one lactam having at least one hydroxyl functional group, wherein the lactam may be in a blend with one or more optional alcohol(s). Among other properties, the modified natural compounds may exhibit dispersibility or solubility characteristics in water and/or alcohols. The invention further provides a wide variety of compositions comprising the modified natural compounds.Type: ApplicationFiled: July 25, 2011Publication date: October 31, 2013Inventors: Osama M. Musa, Ezat Khosravi
-
Patent number: 8518874Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: GrantFiled: October 23, 2009Date of Patent: August 27, 2013Assignee: Virobay, Inc.Inventors: Michael Graupe, John O. Link, Chandrasekar Venkataramani
-
Patent number: 8431721Abstract: The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol represents a single or a double bond; and R1, R2 and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.Type: GrantFiled: June 20, 2011Date of Patent: April 30, 2013Assignee: Constar International, Inc.Inventors: Girish Nilkanth Deshpande, Paul David Weipert, Michael W. Ensley
-
Publication number: 20130096318Abstract: Methods and materials for producing meso-biliverdin are provided where the methods include reacting phycocyanobilin with an amphoteric compound in a solvent to yield meso-biliverdin.Type: ApplicationFiled: October 12, 2012Publication date: April 18, 2013Applicant: Utah State UniversityInventor: Utah State University
-
Publication number: 20130079528Abstract: A method of making a compound of Formula I? comprises reacting a compound of the formula DLCHO, with a compound of the formula to produce the compound of Formula I?. Methods of using the compounds are also described, particularly as intermediates for the synthesis of porphyrin rods, which porphyrin rods are in turn useful for (among other things) the production of molecular memory devices.Type: ApplicationFiled: August 31, 2012Publication date: March 28, 2013Inventors: Jonathan S. Lindsey, Lianhe Yu, Patchanita Thamyongkit, Anil D. Bhise
-
Publication number: 20130035484Abstract: A compound of formula (I): which is substantially free of any of the corresponding compound of formula (IB): methods of making such compounds, and the further transformation of such compounds.Type: ApplicationFiled: April 15, 2011Publication date: February 7, 2013Applicant: SPIROGEN DEVELOPMENTS SÀRLInventors: Philip Wilson Howard, Luke Masterson, Arnaud Tiberghien
-
Patent number: 8362035Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: GrantFiled: July 3, 2012Date of Patent: January 29, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
-
Patent number: 8232293Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: GrantFiled: September 15, 2009Date of Patent: July 31, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
-
Publication number: 20120148514Abstract: Described is a class of symmetrical and asymmetrical N-alkyl lactam ethers. One preferred ether is bis-N-ethyl pyrrolidone ether. Preferred compositions and uses of the ethers are in performance chemicals, personal care, and pharmaceutical fields, where they function a variety of roles, including as a solvent, solubilizer, freezing point depressor, diluent, extracting agent, cleaning agent, degreaser, absorbent and/or dispersion agent.Type: ApplicationFiled: November 15, 2011Publication date: June 14, 2012Applicant: ISP INVESTMENTS INC.Inventors: Osama M. Musa, Kolazi S. Narayanan
-
Patent number: 8163793Abstract: The invention relates to a compound of formula (I) wherein A, R1-R6 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: GrantFiled: April 16, 2010Date of Patent: April 24, 2012Assignee: Hoffman-La Roche Inc.Inventors: Rubén Alvarez Sánchez, David Banner, Simona M. Ceccarelli, Uwe Grether, Wolfgang Haap, Peter Hartman, Guido Hartmann, Hans Hilpert, Holger Kuehne, Harald Mauser, Jean-Marc Plancher
-
Publication number: 20120088705Abstract: The subject of the invention is an etherpyrrolidone carboxylic acid of the formula (1) in which R1 is a C1-C6 hydrocarbon group with 1-4 oxy groups R2 is H, CH3, CH2CH3 (A-O) is a (poly)alkylene glycol unit containing one or more C2-C4 alkoxy groups or a mixture of plural C2-C4 alkoxy groups, at least one alkoxy group being a butoxy or propoxy group M is hydrogen, alkali metal, alkaline earth metal or an ammonium group y is 1 or 2 x is 1, 2, 3 or 4.Type: ApplicationFiled: May 19, 2010Publication date: April 12, 2012Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Rainer Kupfer, Carsten Cohrs, Alexander Roesch
-
Publication number: 20110312890Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.Type: ApplicationFiled: August 1, 2011Publication date: December 22, 2011Applicant: SIGNATURE R&D HOLDINGS, LLCInventor: V. Ravi Chandran
-
Patent number: 8067651Abstract: The invention provides compounds of the formula 1 in which A is a C2- to C4-alkylene group x is from 1 to 100 R1 is C1-C30-alkyl, C2-C30-alkenyl, C7-C30-alkylaryl R2 is an aliphatic, cycloaliphatic or aromatic radical which contains at least one structural unit of the formula 2 ?and y is from 0 to 100, with the proviso that y is from 1 to 100 when R2 is of the formula 2, and their use in amounts of from 0.01 to 2% by weight for preventing the formation of gas hydrates in aqueous phases which are in contact with a gaseous, liquid or solid organic phase.Type: GrantFiled: August 1, 2008Date of Patent: November 29, 2011Assignee: Clariant Finance (BVI) LimitedInventors: Dirk Leinweber, Alexander Roesch, Michael Feustel
-
Patent number: 7985594Abstract: The present invention provides methods for performing dynamic nuclear polarization using biradicals with a structure of formula (I) as described herein. In general, the methods involve (a) providing a frozen sample in a magnetic field, wherein the frozen sample includes a biradical of formula (I) and an analyte with at least one spin half nucleus; (b) polarizing the at least one spin half nucleus of the analyte by irradiating the frozen sample with radiation having a frequency that excites electron spin transitions in the biradical; (c) optionally melting the sample to produce a molten sample; and (d) detecting nuclear spin transitions in the at least one spin half nucleus of the analyte in the frozen or molten sample. The present invention also provides biradicals with a structure of formula (I) with the proviso that Q1 and Q2 are different when X1 and X2 are —O—. The present invention also provides methods for making biradicals with a structure of formula (IA) as described herein.Type: GrantFiled: May 10, 2007Date of Patent: July 26, 2011Assignee: Massachusetts Institute of TechnologyInventors: Robert G. Griffin, Kan-Nian Hu, Timothy M. Swager, Changsik Song, Eric Dane
-
Publication number: 20110171171Abstract: A compound of Formula 1.1A: 1.1A or salt thereof, as well as methods of making compounds of Formula 1.1A, methods of using compounds of Formula 1.1A to treat proliferative disorders such as cancer, and related compounds, composition, and methods.Type: ApplicationFiled: June 26, 2009Publication date: July 14, 2011Applicant: Aegera Therapeutics, Inc.Inventors: Alain Laurent, Melanie Proulx, Yannick Rose, James B. Jaquith, Stephen Morris
-
Patent number: 7923562Abstract: Bifunctional linkers are provided that comprise a photocleavable moiety flanked by two different amine reactive moieties. In some embodiments the photocleavable moiety is a dimethoxynitrobenzyl moiety. In other embodiments the photocleavable moiety is 8-bromo-7-hydroxyquinoline. In other embodiments the photocleavable moiety is nitrodibenzofuran. In other embodiments the photocleavable moiety is 6-bromo-7-hydroxycoumarin-4-ylmethyl. The linkers find use in synthetic methods, including the generation of photocleavable oligonucleotides, e.g. caged morpholinos.Type: GrantFiled: June 16, 2009Date of Patent: April 12, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: James K. Chen, Surajit Sinha, Ilya Shestopalov, Xiaohu Ouyang
-
Patent number: 7897776Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.Type: GrantFiled: April 23, 2008Date of Patent: March 1, 2011Assignee: Salutria Pharmaceuticals LLCInventors: M. David Weingarten, Charles Q. Meng, James A. Sikorski, Raymond Ng, Wei Zhang
-
Publication number: 20100297405Abstract: Monomeric or polymeric compounds comprising at least one moiety of the formula (Ia) wherein X is CR, where R is H or a substituent as defined in claim 1, or is another ketopyrrole moiety e.g. of the formula (1b) or (1c) with this moiety and all other symbols are as defined in claim 1, show good solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).Type: ApplicationFiled: October 16, 2008Publication date: November 25, 2010Applicant: BASF SEInventors: Jean-Charles Flores, Ulrich Berens, Frank Bienewald, Hans Jurg Kirner, Mathieu G.R. Turbiez
-
Patent number: 7772159Abstract: The invention provides a new process for the preparation of polypyrrolinones (I) of various sizes which have found to be useful peptidomimetics. One aspect of the invention is a new process utilizing ?-amino-?-substituted-valerolactones as synthons. A second aspect of the invention is a process for the synthesis of polypyrrolinones using solid-phase techniques.Type: GrantFiled: July 20, 2004Date of Patent: August 10, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Amos B. Smith, III, Hu Liu, Hiroyuki Ikumura, Ralph F. Hirschmann
-
Patent number: 7745641Abstract: The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): {wherein W represents a nitrogen atom or —CH—; X represents —C(?O)— or —CHR4— (wherein R4 represents a hydrogen atom, or the like}; R1 represents a group represented by the following formula: [wherein Q1 represents a nitrogen atom or —CR8— (wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like). Q2 represents —NR15— (wherein R15 represents a hydrogen atom, or the like) and R5 and R6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof, and the like.Type: GrantFiled: April 19, 2006Date of Patent: June 29, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Chikara Murakata, Nobuyoshi Amishiro, Toshiyuki Atsumi, Yoshinori Yamashita, Takeshi Takahashi, Ryuichiro Nakai, Hisashi Tagaya, Hiroko Takahashi, Jun Funahashi, Junichiro Yamamoto, Yuichi Fukuda
-
Publication number: 20090270454Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.Type: ApplicationFiled: April 23, 2008Publication date: October 29, 2009Inventors: M. David Weingarten, Charles Q. Meng, James A. Sikorski, Raymond Ng, Wei Zhang
-
Patent number: 7608592Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: GrantFiled: June 28, 2006Date of Patent: October 27, 2009Assignee: ViroBay, Inc.Inventors: Michael Graupe, John O. Link, Chandrasekar Venkataramani
-
Publication number: 20090203762Abstract: The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.Type: ApplicationFiled: February 2, 2009Publication date: August 13, 2009Inventors: MICHAEL L. PENDRAK, DAVID D. ROBERTS
-
Patent number: 7498447Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: July 17, 2007Date of Patent: March 3, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090043146Abstract: The invention provides compounds of the formula 1 in which A is a C2- to C4-alkylene group x is from 1 to 100 R1 is C1-C30-alkyl, C2-C30-alkenyl, C7-C30-alkylaryl R2 is an aliphatic, cycloaliphatic or aromatic radical which contains at least one structural unit of the formula 2 ?and y is from 0 to 100, with the proviso that y is from 1 to 100 when R2 is of the formula 2, and their use in amounts of from 0.01 to 2% by weight for preventing the formation of gas hydrates in aqueous phases which are in contact with a gaseous, liquid or solid organic phase.Type: ApplicationFiled: August 1, 2008Publication date: February 12, 2009Inventors: Dirk Leinweber, Alexander Roesch, Michael Feustel
-
Patent number: 7482475Abstract: Disclosed herein is a compound having a structure Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: August 9, 2007Date of Patent: January 27, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Robert M. Burk
-
Patent number: 7476747Abstract: A compound comprising or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: GrantFiled: March 6, 2006Date of Patent: January 13, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7309800Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.Type: GrantFiled: November 3, 2006Date of Patent: December 18, 2007Assignee: Glaxo Group LimitedInventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Ann Louise Walker
-
Patent number: 7196112Abstract: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.Type: GrantFiled: July 16, 2004Date of Patent: March 27, 2007Assignee: Biogen Idec MA Inc.Inventors: Wen-Cherng Lee, R. Blake Pepinsky, Mark Cornebise, Daniel Scott, Russell C. Petter
-
Patent number: 7193067Abstract: Mono- and Bis-Azo/Hydrazone Pyrrole Pigments and Methods for preparing same.Type: GrantFiled: August 23, 2005Date of Patent: March 20, 2007Inventors: Terence Chamberlain, Norman W. Smith, Donald T. DeRussy
-
Patent number: 7151118Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.Type: GrantFiled: October 16, 2002Date of Patent: December 19, 2006Assignee: Glaxo Group LimitedInventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Ann Louise Walker
-
Patent number: RE40525Abstract: A racemate diastereoisomer and optical isomer of a compound of formula (I): wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which may be optionally substituted with C1-6 alkyl; C1-6 alkoxy; C1-6 alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6 alkyl; amido; or (lower alkyl)amide; or B is an acyl derivative of formula R4—C(O)—; a carboxyl derivative of formula R4—O—C(O)—; an amide derivative of formula R4—N(R5)—C(O)—; a thioamide derivative of formula R4—N(R5)—C(S)—; or a sulfonyl of formula R4—SO2; R5 is H or C1-6 alkyl; and Y is H or C1-6 alkyl; R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, amido, (lower alkyl)amido, C6 or C10 aryl, or C7-16 aralkyl; R2 is C2—R20, NH—R20, O—R20 or S—R20, wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10 (alkylcycloalkyl), all of which being optionally mono-, di- or tri-Type: GrantFiled: September 30, 2005Date of Patent: September 30, 2008Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Montse Llinas-Brunet, Murray D. Bailey, Dale R. Cameron, Anne-Marie Faucher, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Marc-André Poupart, Jean Rancourt, Youla S. Tsantrizos, Dominik M. Wernic